

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—Joint Research and Development Venture Agreement for Seismic Technology**

Notice is hereby given that, on February 10, 1995, pursuant to the National Cooperative Research and Production Act of 1993, 15 U.S.C. § 4301 *et seq.* ("the Act"), Paul W. Pendorf, President of XXsys Technologies, Inc. has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties are: XXsys Technologies, Inc./ Composite Retrofit Corp., San Diego, CA; Hercules Incorporated, Wilmington, DE; and Trans-Science Corp., La Jolla, CA. The general area of planned activity is to develop and demonstrate low cost manufacturing process and design/ sensor technologies for seismic upgrading of bridge columns. An award from the Advanced Technology Program, National Institute of Standards and Technology, U.S. Department of Commerce will partially fund this joint Research and Development Activity.

**Constance K. Robinson,**  
*Director of Operations Antitrust Division.*  
[FR Doc. 95-10312 Filed 4-26-95; 8:45 am]  
BILLING CODE 4410-01-M

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—Gas Pipeline Monitoring for Third-Party Damage**

Notice is hereby given that, on February 21, 1995, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. § 4301 *et seq.* ("the Act"), Southwest Research Institute ("SwRI") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties are: Tokyo Gas Company, LTD., Yokohama JAPAN; Osaka Gas Company,

Ltd., Osaka, JAPAN; and Toho Gas Company, Ltd., Nagoya JAPAN. The general areas of planned activities are to determine what technologies are available for monitoring of damage to gas pipelines by conducting a literature survey concerning detection of third-party damage to pipelines, sensing systems being utilized and signal processing technologies available in order to advise the participants of such a system's detection capabilities to display the location of damage, to announce the detection of damage, and to indicate the grade or degree of damage which has occurred; by exploring related detected technologies and by evaluating the information gathered in order to recommend one or more technical approaches for further research and system development.

Membership in the program is closed and SwRI intends to file additional written notification if there are any changes in planned activities.

**Constance K. Robinson,**  
*Director of Operations, Antitrust Division.*  
[FR Doc. 95-10314 Filed 4-26-95; 8:45 am]  
BILLING CODE 4410-01-M

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—Petroleum Environmental Research Forum**

Notice is hereby given that, on March 1, 1995, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. § 4301 *et seq.* ("the Act"), the Petroleum Environmental Research Forum ("PERF") has filed written notification simultaneously with the Attorney General and the Federal Trade Commission disclosing a change in project membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Murphy Oil USA, Inc., has terminated its membership with PERF.

No other changes have been made in either the membership or planned activities of PERF. Membership remains open, and PERF intends to file additional written notification disclosing all changes in membership.

On February 10, 1986, PERF filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on March 14, 1986 (51 FR 8903).

The last notification was filed with the Department on January 10, 1995. A notice was published in the **Federal**

**Register** pursuant to Section 6(b) of the Act on March 1, 1995 (60 FR 11115).

**Constance K. Robinson,**  
*Director of Operations, Antitrust Division.*  
[FR Doc. 95-10311 Filed 4-26-95; 8:45 am]  
BILLING CODE 4410-01-M

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 24, 1995, Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
2,5-Dimethoxyamphetamine (7396)	I.
Difenoxin (9168) .....	I.
Methylphenidate (1724) .....	II.
Codeine (9050) .....	II.
Oxycodone (9143) .....	II.
Hydromorphone (9150) .....	II.
Diphenoxylate (9170) .....	II.
Hydrocodone (9193) .....	II.
Levorphanol (9220) .....	II.
Meperidine (9230) .....	II.
Meperidine intermediate-A (9232)	II.
Meperidine intermediate-B (9233)	II.
Meperidine intermediate-C (9234)	II.
Methadone (9250) .....	II.
Methadone intermediate (9254) ...	II.
Morphine (9300) .....	II.
Oxymorphone (9652) .....	II.
Alfentanil (9737) .....	II.
Sufentanil (9740) .....	II.
Carfentanil (9743) .....	II.
Fentanyl (9801) .....	II.

The firm plans to manufacture the listed control substances in bulk supply final dosage form for manufacturers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application and may also file a written request for a hearing thereon in accordance with 21 CFR 1301.54 and in the form prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistance Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than May 30, 1995.